Idealpharma
Idealpharma has been active since 2004 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €55k and a net result of €-193k. Equity is growing by ~3.8% per year across the filed fiscal years. Its solvency ranks better than 27% of 480 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
| Equity | €55k |
| Net result | €-193k |
| Better than sector | 27% |
| Active | 22 yrs |
Fragile profile, watch profitability in particular.
All 5 axes are computed from data Checked has read.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 6.9% | 21.2% | |
| Net result | €-193k | €32k | |
| Equity | €55k | €163k | |
| Gross operating margin | €6k | €281k | |
| Total assets | €804k | €900k |
Figures by fiscal year and ratios
| Fiscal year | 2025 |
|---|---|
| Deposit | abbreviated schema |
| Revenue | - |
| EBITDA | €-131k |
| Net profit | €-193k |
| Cash flow | €-176k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €804k |
| Equity | €55k |
| Debt | €749k |
| of which ≤ 1y | €691k |
| of which > 1y | €58k |
| Working capital | €27k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 1.04 |
| Quick ratio | 0.82 |
| Working capital ratio | 3.4% |
| Solvency | 6.9% |
| Debt / equity | 13.50 |
| Long-term debt ratio | 1.05 |
| Interest coverage | -2.90 |
| Gross margin | - |
| Net margin | - |
| ROA | -24.0% |
| ROE | -348.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (22 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €804k |
| Fixed assets | 21/28 | €87k |
| Tangible fixed assets | 22/27 | €87k |
| Current assets | 29/58 | €718k |
| Stocks & contracts in progress | 3 | €153k |
| Amounts receivable within one year | 40/41 | €555k |
| Cash & bank | 54/58 | €7k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €804k |
| Equity | 10/15 | €55k |
| Contributions / capital | 10/11 | €19k |
| Reserves | 13 | €42k |
| Accumulated profits (losses) | 14 | €-5k |
| Amounts payable | 17/49 | €749k |
| Amounts payable after one year | 17 | €58k |
| Amounts payable within one year | 42/48 | €691k |
| Trade debts payable within one year | 44 | €166k |
| Income statement | ||
| Gross operating margin | 9900 | €6k |
| Operating result | 9901 | €-148k |
| Financial charges | 65 | €45k |
| Result before taxes | 9903 | €-193k |
| Net result for the period | 9904 | €-193k |
| Result to be appropriated | 9905 | €-193k |
Former directors (1)
-
Erik Van NuffelDirectorState Gazette act 24135141 (18-09-2024)Former- → 18-09-2024
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company (pre-2019)(015) |
| Incorporation | 08-04-2004 |
| Status | Active |
| Postal code | 2660 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11383B0469/00X005 | Flanders | 237 m² | 1 · 197 m² | 10.2 m · 2 fl. |
We know of 5 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
18-09-2024 2 directors appointed, 1 resigning
- Tim De CLercq, Dagelijks bestuur
- Carl Dierckx, Dagelijks bestuur
- Erik Van Nuffel, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Erik Van Nuffel",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "de_plein_droit_dissolution",
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De Algemene vergadering beslist op heden, 30 juli 2024, tot ontslag van Erik Van Nuffel waarbij geen kwijting wordt verleend.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Tim De CLercq",
"address": null,
"birth_date": null,
"profession": "advocaat",
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": null,
"name": "Talo Advocaten",
"address": "2000 Antwerpen, Amerikalei 79",
"country": "BE",
"legal_form": null
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De vergadering verleent aan Mr. Tim De CLercq en Mr. Carl Dierckx, advocaten bij Talo Advocaten met kantoor te 2000 Antwerpen, Amerikalei 79, een bijzonder volmacht om alle nodige documenten als gevolg van de beslissingen genomen in deze algemene vergadering neer te leggen ter griffie van de Onderne",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Carl Dierckx",
"address": null,
"birth_date": null,
"profession": "advocaat",
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": null,
"name": "Talo Advocaten",
"address": "2000 Antwerpen, Amerikalei 79",
"country": "BE",
"legal_form": null
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De vergadering verleent aan Mr. Tim De CLercq en Mr. Carl Dierckx, advocaten bij Talo Advocaten met kantoor te 2000 Antwerpen, Amerikalei 79, een bijzonder volmacht om alle nodige documenten als gevolg van de beslissingen genomen in deze algemene vergadering neer te leggen ter griffie van de Onderne",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-09-18",
"filing_date": "2024-09-05",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2024-07-30",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0864.605.936",
"name_full": "Idealpharma",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}| Legal nameNL | Idealpharma |